SCHEMBL5546273

SCHEMBL5546273

CCOC(=O)c1cccc(CO[C]=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.59
CYP4A11 Q02928 1/20 0.59
MAPT P10636 3/20 0.53
RAB9A P51151 3/20 0.53
ALDH1A1 P00352 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.53
MEP1B Q16820 1/20 0.52
CA2 P00918 4/20 0.49
KDM4E B2RXH2 1/20 0.47
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA7 P43166 3/20 0.46
CA9 Q16790 3/20 0.46
CA14 Q9ULX7 3/20 0.46
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539850 0.86 CYP4F2 (0.64) CYP4F2CYP4A11MAPTRAB9AALDH1A1
SCHEMBL5543239 0.85 LOXL2 (0.62) CYP4F2CYP4A11MAPTRAB9AALDH1A1
SCHEMBL23635693 0.83 CYP4F2 (0.64) CYP4F2CYP4A11MAPTRAB9AALDH1A1
SCHEMBL27980684 0.83 CYP4F2 (0.64) CYP4F2CYP4A11MAPTRAB9AALDH1A1
SCHEMBL129801 0.82 CYP4F2 (0.71) CYP4F2CYP4A11MAPTRAB9AALDH1A1
SCHEMBL5543889 0.81 CA1 (0.61) MAPTRAB9AALDH1A1SMN1; SMN2NPC1
SCHEMBL128387 0.80 CYP4F2 (0.72) CYP4F2CYP4A11MAPTRAB9AALDH1A1
SCHEMBL7276073 0.80 FOLH1 (0.56) RAB9ASMN1; SMN2NPC1KMT2ATP53
SCHEMBL2089661 0.80 CYP4F2 (0.68) CYP4F2CYP4A11MAPTRAB9AALDH1A1
SCHEMBL5546275 0.79 CYP4F2 (0.59) CYP4F2CYP4A11MAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP4F2 954/4885CYP4A11 1804/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.